Xbrane Biopharma AB Wins FDA Nod For Lucamzi Biosimilar
Oct 27, 2026, Xbrane Biopharma AB received FDA approval for Lucamzi (ranibizumab-blrz), a biosimilar to Lucentis, and is preparing a US launch in 2027 with partners.
Material Details
- FDA approves Lucamzi (ranibizumab-blrz), regulatory clearance enables US commercialization of a high-value ophthalmology biosimilar.
- US launch planned during 2027 sets timing for potential revenue inflection; execution and pricing will drive uptake.
- Biosimilar to Lucentis – Targets a well-known reference drug; physician familiarity can speed adoption.
- Phase 3 showed equivalent efficacy Clinical comparability reduces adoption risk and supports payer coverage.
- Anti-VEGF market ≈ €9B sales Large addressable market; pricing and share capture key to impact.
Context by AI Analyst
This is a late-stage regulatory milestone in Xbrane’s strategy to commercialize ophthalmology biosimilars. Next catalysts: partner launch details, US pricing/reimbursement, and early sales/market share updates post-2027 launch.
Based on the original press release from Xbrane Biopharma AB distributed by MFN by Modular Finance.
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Hagastaden, Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE.
